Successful development of prototype assays

International medical diagnostics company Panbio Limited today announced that it had developed two prototype immunoassays using their proprietary panDA Homogeneous Assay technology.

Panbios prototype panDA Homogeneous Assays are able to specifically and accurately detect and differentiate IgG antibodies induced by infection with Herpes Simplex Virus (HSV) 1 and HSV 2 in validated serum samples.

Commenting on the achievement of this milestone, Panbio Acting CEO, Dr Stuart Hazell said, This is clear evidence that the panDA Homogeneous Assay technology is capable of differentiating similar analytes with high specificity, which is an area where other homogeneous immunoassay platforms typically flounder. Successfully demonstrating that the key components of the system and the analyte interact specifically and generate a clear signal represents an important breakthrough.

The announcement marks the achievement of a key milestone in developing the panDA Homogeneous Immunoassay technology. We have achieved the first functional prototype assays based on Panbios proprietary panDA Homogeneous Assay technology within the timeframe previously indicated to the market, said Panbio Chairman, Maj Gen (Ret) Peter Arnison.

Key advances achieved in the development of the prototype panDA Homogenous Assays include:
Sensitive and specific detection of a type specific antibody, IgG, induced by specific infection with either HSV 1 or HSV 2, with little or no cross reactivity between analytes.
Performance data obtained using a true homogeneous immunoassay format. A serum sample is added to a master reagent mix, which if positive produces a colorimetric signal that may be detected shortly thereafter.
Results that are comparable with those obtained by testing with the market leading kits using the current ELISA technology.
Generation of performance data by in-house testing of a panel of 150 samples.
The assay system

Contact: Dr Stuart Hazell
Research Australia

Page: 1 2 3

Related biology news :

1. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
2. Successful one year gene therapy trial for Parkinsons disease announced by Neurologix
3. Successful transplantation from pig embryos to mice
4. Successful cell engineering may lead to mad cow prevention, say researchers
5. Successful test of single molecule switch opens the door to biomolecular electronics
6. Teamwork between 2 key proteins necessary for normal development and regulation of red blood cells
7. MicroRNA works with Ago2 protein to regulate blood cell development
8. Study provides new data about the laws governing embryo development in organisms
9. Common environmental chemicals in diet affect fetal ovarian development
10. The Cancer Genome Atlas awards funds for technology development
11. Marine worm opens new window on early cell development

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: